Oseltamivir is an attractive drug for ITP since it specifically targets a pathophysiologic mechanism that appears to be important for the development of ITP and has a benign side effect profile compared to standard ITP therapy. This pilot, proof-of-concept, randomized controlled clinical trial has the potential to dramatically change the treatment of ITP.

Canada

https://clinicaltrials.gov/ct2/show/NCT03520049?recrs=a&cond=ITP&draw=4&rank=24

Recruiting